All In Biotech

Drug Trial Radar · NCT01436500

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

A Multi-Center, Double-Blind, Randomized, Controlled Study to Determine the Safety and Pharmacokinetics of Ifetroban Injection in Hepatorenal Syndrome

Last checked: Nov 19, 2026Latest source record: Mar 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

55

Actual

Start

Oct 2011

Primary completion

Jun 2015

Study completion Jul 2015

Sponsor

Lead sponsor
Cumberland PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 19, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of ifetroban in the treatment of hepatorenal syndrome (HRS) in hospitalized adult patients to assess the safety and pharmacokinetics of 3 days of intravenous ifetroban.

Conditions

  • Hepatorenal Syndrome

Interventions

  • Ifetroban InjectionDrug

    Ifetroban sodium injectable, diluted in sterile water with 5% dextrose

  • PlaceboDrug

    Sterile water with 5% Dextrose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Half-life (T-1/2) of Ifetroban and Ifetroban AcylglucuronideTime frame: 3 days
  2. Pharmacokinetic Parameters (Exposure) of Ifetroban and Ifetroban Acylglucuronide After Three Days of TreatmentTime frame: 3 days
  3. Pharmacokinetic Parameters (Concentration) of Ifetroban and Ifetroban Acylglucuronide After Three Days of TreatmentTime frame: 3 days

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - Arizona

    Phoenix, Arizona

  • UCSD, Hillcrest Medical Center Hospital

    La Jolla, California

  • UCSF (University of California-San Francisco)

    San Francisco, California

  • Emory University Hospital

    Atlanta, Georgia

  • Indiana University (Division of Gastroenterology/Hepatology)

    Indianapolis, Indiana

  • University of Michigan Hospital

    Ann Arbor, Michigan

  • NYU Langone Medical Center

    New York, New York

  • The Ohio State University

    Columbus, Ohio

  • Baylor All Saints Medical Center

    Fort Worth, Texas

  • University of Utah Health Sciences Center

    Salt Lake City, Utah

  • Virginia Commonwealth University

    Richmond, Virginia

  • MIDAS Multispeciality Hospital PVT LTD

    Nagpur, Maharashtra, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.